company-builder
(3)
David Steinberg
David Steinberg is Chief Business Officer at Formation Bio, an AI-native pharmaceutical company in New York, where he runs in- and out-licensing and pipeline strategy. A serial biotech company builder, he co-founded PureTech Health and served as its Chief Innovation Officer, was a General Partner at Longwood Fund, and founded or led a string of NASDAQ-listed and venture-backed companies including Pyxis Oncology, Vor Biopharma, Vedanta Biosciences and Be Biopharma. He pairs a Cornell biology degree with a University of Chicago Booth MBA and a career that began in R&D and strategy consulting.
Peter DiLaura
Peter DiLaura is the CEO and Board Director of Helicore Biopharma, a San Mateo biotech building long-acting antibody-peptide conjugates that go after obesity by neutralizing the GIP hormone in the bloodstream rather than blocking its receptor. With nearly three decades of company-building behind him - CEO roles at Initial Therapeutics and Second Genome, business and strategy chief at Sonoma Biotherapeutics, and time as an Entrepreneur-in-Residence at Third Rock Ventures - he is the operator brought in to turn a $65M Series A and a clinic-ready antibody into medicines that aim for quarterly dosing and better-quality weight loss.
Julie Grant
Julie Grant is a General Partner at Canaan, a $5B technology and healthcare venture capital firm, where she leads biopharma investments and company formation on the West Coast. She co-founded and served as founding CEO of Day One Biopharmaceuticals, a purpose-built pediatric oncology company that grew to a $1.5B+ valuation and was later acquired by Servier. A Yale-educated molecular biophysicist who went on to Stanford MBA and Cambridge MPhil, Grant brings rare operational depth to venture - having sat in the CEO chair before returning to investing. In 2023, President Biden appointed her to the National Cancer Advisory Board. She is the fourth woman to become a General Partner at Canaan.